<DOC>
	<DOCNO>NCT00004923</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness docetaxel irinotecan treating patient advance solid tumor .</brief_summary>
	<brief_title>Docetaxel Irinotecan Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose irinotecan combine docetaxel patient advance solid malignancy . II . Determine dose limit toxicity regimen patient . III . Assess antitumor activity regimen patient . OUTLINE : This dose escalation , multicenter study irinotecan . Patients receive docetaxel IV 1 hour follow immediately irinotecan IV 30 minute day 1 , 8 , 15 , 22 . Treatment continue every 6 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow every 3 month 1 year , every 6 month thereafter . PROJECTED ACCRUAL : Approximately 15-25 patient accrue study .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven solid malignancy effective therapy currently available CNS metastasis allow CNS disease stable least 4 week follow completion surgery and/or radiotherapy PATIENT CHARACTERISTICS : Age : Over 18 Performance status : At least 3 month Life expectancy : ECOG 02 Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.2 mg/dL SGOT and/or SGPT great 1.5 time upper limit normal ( ULN ) ( great 2.5 time ULN allow alkaline phosphatase great ULN ) Alkaline phosphatase great 2.5 time ULN ( great 4 time ULN allow SGOT and/or SGPT great ULN ) Renal : Creatinine clearance least 55 mL/min Other : HIV negative No active infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent medical condition would preclude compliance study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy regimen contain topotecan , irinotecan , docetaxel At least 4 week since prior chemotherapy ( 6 week since prior nitrosoureas , melphalan , mitomycin ) Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior wide field radiotherapy No prior radiotherapy great 20 % bone marrow Surgery : See Disease Characteristics Recovered prior surgery Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>